# A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects

> **NCT07079618** · PHASE1 · COMPLETED · sponsor: **Beijing Sungen Biomedical Technology Co., Ltd** · enrollment: 49 (actual)

## Conditions studied

- Anterior Myocardial Infarction

## Interventions

- **DRUG:** SGC001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07079618
- **Lead sponsor:** Beijing Sungen Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-20
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07079618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07079618, "A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07079618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*